← Back to Screener
Cabaletta Bio, Inc. Common Stock (CABA)
Price$3.52
Favorite Metrics
Price vs S&P 500 (26W)37.09%
Price vs S&P 500 (4W)8.66%
Market Capitalization$378.50M
All Metrics
Book Value / Share (Quarterly)$1.12
P/TBV (Annual)7.65x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.32
Price vs S&P 500 (YTD)52.61%
EPS (TTM)$-2.28
10-Day Avg Trading Volume1.85M
EPS Excl Extra (TTM)$-2.28
EPS (Annual)$-2.10
ROI (Annual)-123.71%
Cash / Share (Quarterly)$1.33
ROA (Last FY)-101.68%
EBITD / Share (TTM)$-2.13
ROE (5Y Avg)-68.89%
Cash Flow / Share (Annual)$-1.32
P/B Ratio3.38x
P/B Ratio (Quarterly)1.88x
Net Income / Employee (Annual)$-1
ROA (TTM)-90.19%
EPS Incl Extra (Annual)$-2.10
Current Ratio (Annual)2.77x
Quick Ratio (Quarterly)2.66x
3-Month Avg Trading Volume2.65M
52-Week Price Return191.85%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.86
52-Week High$3.78
EPS Excl Extra (Annual)$-2.10
CapEx CAGR (5Y)13.94%
26-Week Price Return41.08%
Quick Ratio (Annual)2.66x
13-Week Price Return53.85%
Total Debt / Equity (Annual)0.21x
Current Ratio (Quarterly)2.77x
Enterprise Value$319.152
Book Value / Share Growth (5Y)-24.49%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$1.33
3-Month Return Std Dev92.75%
Net Income / Employee (TTM)$-1
ROE (Last FY)-149.80%
EPS Basic Excl Extra (Annual)$-2.10
Total Debt / Equity (Quarterly)0.21x
EPS Incl Extra (TTM)$-2.28
ROI (TTM)-104.75%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.55
Price vs S&P 500 (52W)162.02%
Year-to-Date Return55.25%
5-Day Price Return7.26%
EPS Normalized (Annual)$-2.10
ROA (5Y Avg)-54.58%
Month-to-Date Return26.39%
Cash Flow / Share (TTM)$-1.64
EBITD / Share (Annual)$-2.13
ROI (5Y Avg)-62.80%
EPS Basic Excl Extra (TTM)$-2.28
P/TBV (Quarterly)4.97x
P/B Ratio (Annual)1.88x
Book Value / Share (Annual)$1.12
Price vs S&P 500 (13W)53.16%
Beta3.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-121.73%
52-Week Low$1.06
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.19
4.19
4.19
4.19
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
CABACabaletta Bio, Inc. Common Stock | — | — | — | — | $3.52 |
AMGNAmgen Inc | 5.13x | 9.95% | 73.30% | 2.93% | $349.39 |
GILDGilead Sciences Inc | 5.84x | 2.40% | 78.83% | 133.64% | $138.55 |
ARGXargenx SE American Depositary Shares | 12.46x | 89.56% | 150.91% | — | $828.35 |
BNTXBioNTech SE American Depositary Share | 8.75x | -11.81% | 84.21% | — | $102.12 |
BIIBBiogen Inc. Common Stock | 2.60x | 2.22% | 75.69% | -18.77% | $176.02 |
MRNAModerna, Inc. Common Stock | 11.02x | -39.93% | 70.32% | — | $54.68 |
NBIXNeurocrine Biosciences Inc | 4.49x | 21.45% | 98.18% | 2.31% | $128.41 |
EXELExelixis Inc | 4.96x | 6.85% | 96.39% | 31.10% | $44.38 |
TECHBio-Techne Corp. | 7.60x | 1.64% | 66.60% | -20.58% | $57.36 |
HALOHalozyme Therapeutics, Inc. | 5.74x | 37.55% | 83.62% | 22.89% | $66.64 |
About
Cabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary CAART technology selectively eliminates disease-causing B cells while preserving normal B cells, offering the potential for deep and durable therapeutic effects. The company's CABA platform encompasses multiple strategies applicable across a broad range of autoimmune indications.